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Abstract  
With the increasing burden of chronic diseases on the global population, many stakeholders see 
digital health technologies and devices as potential solutions to improve patient self-management 
of their disease and offer novel treatment methods. Digital health solutions including mobile 
apps, web-based programs, texting, and connected devices have been applied to a wide variety of 
diseases. In recent years, interest in digital health technologies has exploded with almost 200 
digital health related articles published in PubMed in 2019 alone. In particular, digital health 
holds great potential in improving and enhancing the traditional clinical trial by increasing 
patient recruitment and retention and introducing novel assessment and collection methods that 
shift clinical trials from the physical site to the patients’ home. Digital health is poised to 
fundamentally shift how clinical trials are conducted. However, serious challenges from potential 
regulatory restrictions and data privacy issues will need to be addressed before patients, 
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Introduction 
Addressing chronic disease is one of the greatest public health challenges of the modern era. 
According to the Centers for Disease Control, 6 in 10 US adults suffer from a chronic disease 
and 4 in 10 US adults have two or more chronic conditions (Centers for Disease Control and 
Prevention [CDC], 2021). There is an increasing prevalence of chronic conditions and 
comorbidities with more than half of older adults having three or more chronic conditions, such 
as diabetes, cardiovascular disease, cancer, arthritis, mental illness, or high blood pressure 
(American Geriatrics Society, 2012). By 2030, an estimated 170 million Americans will have a 
chronic disease, a staggering increase from 118 million individuals in 1995 (Newman, 2020). 
There is greater healthcare cost and service utilization for patients with chronic disease, where 
those with more conditions have higher associated costs (CDC, 2021). Americans with five or 
more chronic conditions require 14 times more spending than those with no conditions and 
represent 41% of total healthcare costs despite only representing 12% of the population (Buttorff 
et al., 2017). Chronic diseases can have a serious impact on quality of life and lead to future 
disability, thus posing an even greater burden on health services. Many chronic diseases are 
caused by identifiable risk factors and behaviors. Avoiding these key factors and maintaining a 
healthy lifestyle can greatly reduce the likelihood of getting a chronic disease. Health literacy 
and education can play a critical role in informing patients of regularly exercising, eating 
healthy, getting properly screened, and avoiding risky behaviors (Poureslami et al., 2017). For 
those already suffering from a chronic condition, taking their medication is critical to 
maintaining their health and preventing future disability. However, medication adherence is a 
serious problem and it is estimated that patient may be nonadherent to their medications 50% of 
the time (Brown et al., 2016). 
Digital health has been seen as a device or tool to facilitate aspects of healthcare from screening, 
diagnostics, preventative care, and treatment. These devices may serve to support existing health 
interventions or act independently to improve health outcomes. Digital health can be utilized in 
many forms but by enabling and encouraging patients to play active roles in managing their 
health, there has been a focus on their use in chronic diseases and long-term self-management. 
Basic use of digital health may simplify healthcare through digitization, changing the method of 
data collection from paper to digital means. One prominent example is the almost ubiquitous use 
of electronic health records (EHR) over paper forms. However, as digital health evolves, there is 
increasing focus on digitalization, where current processes are improved and altered through the 
use of digital health such as online patient recruitment or medication tracking. Recruitment via 
online modalities has been found to be cost-effective, faster, and achieves higher recruitment 
rates compared to traditional methods (Brøgger-Mikkelsen et al., 2020). Quisel et al (2019) 
found that those who actively used their digital health activity trackers were more likely to be 
adherent to their cardiovascular medication. Digitalization may encourage fundamental behavior 
change in patients through improved efficiency in current process that lower barriers to better 
health behaviors. Digital maturity is the ultimate form where digital health is utilized to innovate 
and fundamentally alter the healthcare paradigm. This is an area that is yet to be explored but a 
revolution in healthcare will occur when patients, physicians, and other healthcare stakeholders 




Figure 1. Digital Health Maturity with Examples 
 
Regardless, the digital health field is manifesting in many forms from mobile devices, software 
as a medical device (SaMD), wearable devices, telemedicine, digital therapeutics, and connected 
drug combination products. The potential of digital health in reducing ever-growing healthcare 
costs, improving outcomes, and providing new treatment modalities cannot be understated. 
Sophisticated digital health technologies can monitor patient outcomes, address gaps in patient 
care, and even support medication optimization. Digital health has been explored as a possible 
solution to issues surrounding adherence, patient administration techniques, disease self-
management, and data outcomes at scale (Bittner, et al., 2019). These technologies are rapidly 
expanding to provide new and innovative ways to improve health outcomes and many healthcare 
stakeholders are exploring how digital health can be used.  
Clinical trials have become increasingly costly following Eroom’s Law, an observation that drug 
discovery is becoming slower and more expensive despite technological advancements (Scannell 
et al., 2012). Developing these technological advancements is extremely costly, and study 
sponsors are under intense scrutiny from competitors, regulatory agencies, and consumers to 
develop effective products. Fierce competition to develop more complex drug products and meet 
FDA requirements has resulted in a convoluted clinical trial process. DiMasi (2016) found that 
the number of study endpoints required by the FDA increased by 86% from 2001-2005 to 2011-
2015 and almost 60% of protocols required a major amendment, which came at a median cost of 
$141,000. As a result, biopharmaceutical companies are looking at how digital health cannot 
only reduce costs, patient burden, and reliance on in-person clinic visits but also improve 
outcome measurements and validation methods. Traditional clinical trials are heavily restrained 
by cost, duration, and patient engagement. Throughout the course of a traditional clinical trial 
there are many lost opportunities to monitor a variety of endpoints for disease progression, 
pharmacokinetics, pharmacodynamics, and safety beyond periodic assessments. End points that 
are monitored may be heavily dependent on patient engagement and willingness and be 
subjected to reliability and validity concerns. Furthermore, the trial endpoints may fulfil FDA 
requirements for drug approval but could be a measurement that is not necessarily meaningful to 
patients or healthcare providers. The biopharmaceutical industry has recognized the potential of 
digital health and is driving innovation with guidance from the FDA’s newly established Digital 
Health Center of Excellence (DHCoE) and other regulatory agencies (Food & Drug 
Administration [FDA], 2020).  
The application and value of digital health to clinical trials is currently being explored. These so 
called decentralized, siteless, remote, or virtual clinical trials integrate digital health in the 
delivery of care to move the trial outside of the clinic and enable remote and real-time collection 
of traditional and novel data. Ideally, digitalization would improve recruitment and retention, 
data collection, and analytics (Inan et al., 2020). Clinical trials have consistently had low patient 
adherence and persistence where Murthy et al. (2004) found that only 8% of cancer patients 
enroll in clinical trials. Recruitment and retainment using digital methods increases access to 
appropriate and diverse patient populations. Clinical trial language is often confusing to patients 
and they may not know what participating in a clinical trial may require of them. Having clear 
guidelines and directions delivered digitally could ensure patients understand the requirements 
needed from them to participate in the clinical trial. Additionally, patients recruited through 
relevant online health communities may be more engaged and willing to complete the clinical 
trial, resulting in better data to determine drug efficacy. With digital recruitment strategies, 
communication methods can be more tailored towards the targeted population to overcome 
communication barriers or issues of mistrust and fear in ethnic groups.  Decentralized trials will 
enable participants to take part in a clinical trial regardless of their location, considerably 
reducing patient burden for travel. Even in so called hybrid trials, where a portion of the clinical 
trial is still conducted at a study site, there is still improved accessibility. Patients may be 
required to meet the investigator in the beginning of the trial but could transition completely to 
virtual meetings as the trial proceeds. Furthermore, telemedicine can improve communication 
between patients and investigators by providing a method for patients to ask questions. For 
investigators of clinical trials, a virtual trial allows them to oversee more patients in a larger area 
compared to traditional clinical trials that limited their oversight to their site. Digital health tools 
can collect more data thorough patient-reported outcomes (PRO) and biomarkers through 
technologies such as wearable and mobile sensors. Digital biomarkers, physiological or 
behavioral measurements collected with a digital device, could revolutionize the types of 
endpoints investigators use to test efficacy (Coravos et al., 2019). The data from digital 
biomarkers is continuously captured and could provide investigators a fuller picture of the 
patient’s health and their response to treatment. With enormous amounts of data, treatments can 
be better tailored or even personalized as more data is fed into algorithms (Coravos et al., 2019). 
Critically, decentralized trials are less expensive because of the advantages of technology. A 
single investigator may oversee a larger number of patients that previously would have required 
multiple sites and staff to manage. Faster recruitment and lessened burden on patients could 
shorten trial duration and speed results. Furthermore, by reducing the need for a physical site, 
sites may be able to oversee more clinical trials simultaneously (Douglas, 2019).  
Methodology 
Digital health is defined as the use of digital devices, tools, technologies, and services by 
healthcare stakeholders (patients, providers, organizations) to empower individuals and 
populations to manage their health and wellness (Snowdon, 2020). Based on this definition and 
in the context of clinical trials, a PubMed search was conducted using the key words: clinical 
trial, digital health, ehealth, mobile health, mhealth, siteless, smartwatch, decentralized, remote 
monitoring (Figure 2a). The PubMed search included studies from inception of the database to 
January 11, 2021 and had no restrictions on the country of origin. Studies were excluded for not 
being in English or irrelevancy because digital health was not used to support or act as a health 
intervention. The search yielded 894 results and 91 were excluded, resulting in a total of 803 
relevant records which were analyzed using natural language processing (NLP) for similarities 
and trends. An additional 15 relevant grey literature, white papers or industry articles, were also 
included in the review.  
The NLP was performed based on the PMIDs from PubMed selected from the literature review 
(Figure 2b). A web crawler was used to extract the articles’ abstract and keywords followed by 
data cleaning, removing stop (informative words) and searching the abstracts for the methods, 
outcome, and conclusion sections. Information retrieval was conducted using NLP processes 
including n-gram, TF-idf, brute force, cosine similarity, and query expansion technique to extract 
the keywords and frequency.  
Figure 2. Methodology 
a. Literature Review Methodology     b. NLP Methodology  
                
Literature Review 
Digital Health and Clinical Trials 
Digital health in clinical trials has manifested in the literature in two distinct ways, exploring the 
potential of digital health or capitalizing on digital health to advance clinical trial research. The 
majority looked to validate the digital health technology in improving health outcomes or better 
understanding users’ preferences and attitude. Clinical trials were traditionally designed 
specifically to test the effectiveness of the digital health tool through randomization in 
intervention and control groups. However, given the emerging digital health field, many of these 
clinical trials are protocols with studies currently in progress or feasibility studies that merely 
explore the potential of digital devices. It is unsurprising that many articles are exploratory rather 
than experimental as it is clear the digital health field is still being developed and the literature 
centered around investigating the potential benefits of digital health. Due to the slow nature of 
the pharmaceutical industry to adopt new technologies or methods to their processes, it is likely 
that industry members will be hesitant to use digital health until the technologies are more 
mature and have been properly validated to demonstrate value to multiple stakeholders. 
Additionally, while some digital health devices may demonstrate efficacy, the extent of these 
benefits may be limited and are insufficient to drive fundamental change in the industry. While 
there has been a shift in thought towards how clinical trials could incorporate digital health to 
collect traditional and novel data, there is still minimal movement by most pharmaceutical 
companies. However, digital health will likely play a more prominent role especially with the 
COVID-19 pandemic that has estimated to have stopped nearly 6,000 trials in the first half of 
2021, more than twice as many compared to previous years (Gaudino, 2020). Many trials 
currently in progress have been forced to adopt some virtual components to become entirely 
virtual or at least partially (Anthes, 2021). Johnson and Johnson’s phase 3 COVID-19 vaccine is 
using a decentralized or virtual trial platform and even post-pandemic this virtual format is likely 
to remain (Adams, 2021).  
The literature review revealed 9 major different types of digital health tools and devices that are 
being explored and can be split into two major categories: mature devices adopted for use in 
healthcare and technologies specifically designed to be used in a digital health platform.  
Types of Digital Health in Clinical Trials  
Table 1. Types of Digital Health Present in Clinical Trials  
 
Mobile Apps 
The most commonly used digital health tool found in the literature search was mobile 
applications (mobile apps). Mobile apps are specific software that is installed by the user onto 
their smartphone, tablet, or similar handheld device. This patient facing tool allows users to 
provide relevant data through the mobile app which collects the data to be shared with the 
researcher. In recent years, this category has exploded in popularity as barriers to the 
development of mobile apps have significantly decreased. Furthermore, smartphone ownership 
has continued to rise where an estimated 1/3 of the world’s population has a smartphone 
(Reisinger, 2014). The number of health-related apps available to any user to download exceeded 
325,000 in 2017 with more than 80,000 publishers (Globe Newswire, 2020). The type of mobile 
app can vary widely depending on its intended use and therapeutic area. Apps can be used to 
simply remind patients to take their medication or record daily PROs such as their mood or 
symptoms. Complex apps would not only solicit PROs but use passive monitoring data inherent 
to the device. Some may facilitate tests to measure specific digital biomarkers to track disease 
progression. Other apps may be an intervention itself designed to create behavioral change.  One 
popular form is gamification, where game-like elements are integrated into the mobile health app 
to encourage patients to perform positive behaviors (Zolfaghari et al, 2021). Most apps focus on 
simple interventions that require minimal software skills and consequently offer limited value. 
Sophisticated features such as machine learning are rare. Despite the widespread popularity of 
mobile health apps, there is limited regulation or validation that using such mobile apps can 
change behavior or improve health outcomes. Critically, very few of these mobile apps have 
demonstrated clinical efficacy. Thus, it is unsurprising that 41.85% (113/270) of the studies in 
the literature review that had a mobile app component were protocols or feasibility studies. The 
prevalence of exploratory studies indicates significant questions remain about the utility of 
mobile health apps. The results of studies utilizing mobile apps vary widely from demonstrating 
a successful intervention to having no effect. StressLess, a mental health app for caregivers, 
reduced stress and depressive symptoms among users in the intervention group over 5-weeks. 
However, on average participants only completed 2.5 of 5 treatment modules and 25% of 
participants were lost to follow-up (Fuller-Tyszkiewicz et al, 2020). In contrast, CONNECT, an 
EHR-integrated app focused on improving medication adherence, demonstrated no significant 
difference between the intervention and control groups for adherence but marginal improvements 
in other components such as e-health literacy (Redfern et al, 2020). Common limitations with 
mobile app focused studies involve possible sampling bias and generalizability to the wider 
target population. Despite online recruitment methods through Facebook and other social media 
sites, some studies struggled to meet sample size targets resulting in underpowered studies. 
Others required the participant to have an iOS or Android device to download and use the mobile 
app. Studies whose apps are restricted to iOS devices may be even more biased given the 
significantly lower markets share of iOS devices (27.47%) compared to Android devices 
(71.93%) (Statcounter, n.d.). Lastly, many mobile apps often rely on self-reported outcomes of 
wellbeing or participation and are at risk for the Hawthorne effect where participants behave 
differently because they know they are being observed.  
Smartphones 
A related digital health utilization of smartphones focuses on the inherent capabilities of the 
smartphone itself. Rather than a conduit for other software or mobile apps, the smartphone itself 
is the digital technology. Most commonly used in a diagnostic manner, patients utilize aspects 
inherent to the device, such as the camera by taking a photo and sending it to their healthcare 
professional (Uthoff, 2020; Leddy, 2019).  The smartphone can allow point of care testing, 
where healthcare or treatment and disease diagnosis can be delivered to the patient at the time of 
care (Kost, 2002).  This could greatly speed diagnosis and reduce the need for in-person 
visitations, freeing up healthcare services. Some studies have shown success such as Dip.io, a 
smartphone urinalysis test that screens for proteinuria to identify those with hypertension for 
possible kidney disease (Leddy, 2019). Individuals were able to screen themselves from their 
home and use of the kit can improve proteinuria screening rates (Leddy, 2019). Limitations of 
smartphone-based studies follow closely with mobile app studies because of the reliance on 
smartphones. Additionally, these studies may require additional support from clinicians and 
laboratories to conduct the test or screening. Collection of the biological sample may be done at 
the patients’ convenience but testing and analysis must still be conducted by a healthcare 
professional. The independence and self-management aspect associated with mobile apps does 
not extend for these smartphone-based screening or diagnostic tests.  
Web-Based 
Web-based or internet-delivered interventions is an expansive category where digital health is 
primary delivered through a computer but the intervention is often supplemented with additional 
digital tools. Patients can access the intervention through a website that exists as a central hub for 
their health data (Moore et al., 2020). Patients may need to complete modules consisting of 
videos with follow-up activities or assignments. One prominent example of this category is 
internet-delivered cognitive behavioral therapy (CBT). Cognitive behavioral therapy has been 
extensively studied in a number of diseases including insomnia, anxiety disorders, and major 
depression. Internet-delivered CBT has been explored and most studies find that it is comparable 
to in-person CBT (Bergström et al., 2010). Furthermore, internet-delivered CBT offers additional 
benefits such as eliminating travel barriers. While care can be delivered in real-time, it is not 
necessary, allowing patients to move through the therapy at their pace and give clinicians ample 
time to respond to questions or consult colleagues. Sleepio, a CBT study for insomnia to treat 
depression, demonstrated patients in the intervention had significantly lower depression severity 
compared to the control group (Cheng et al., 2019). While web-based interventions caught on 
early with the advent of computers, it is clear that stakeholders are moving away from these 
computer-based tools. Most digital health tools today are either directly optimized for 
smartphone use or offer a mobile version.  
Remote Monitoring 
Remote monitoring is the monitoring of activities that were previously conducted on site in a 
clinical trial. Furthermore, with continuous and real-time monitoring, more data can be collected 
to be analyzed and abnormal events can be detected. This allows investigators to frequently 
evaluate patient safety and monitor other critical indicators such as medication adherence or 
treatment compliance (Patel, 2017). Remote monitoring is one of the earliest forms of digital 
health that showed significant interest because of inherent monitoring capabilities in cardiac 
implantable electronic devices (CIEDs). Numerous studies have shown that remote monitoring 
of patients with CIEDS is associated with earlier detection of actionable events, lower 
hospitalization, and lower mortality (Pluta et al, 2020). In the HomeCARE-II study, patients 
were remotely monitored through their implantable devices to validate another measurement for 
fluid accumulation (Maier et al., 2019). There has been particular interest to apply remote 
monitoring beyond cardiovascular monitoring because of the high cost of traditional monitoring 
which typically accounts for 25% of a clinical trial’s total budget (Scannell et al., 2012). The 
EDGE system used commercial pulse oximeters to remotely monitor patients for one year to 
develop an algorithm that predicts COPD exacerbation events (Shah et al., 2017). By combining 
the vital signs obtained from the pulse oximeter, the researchers were able to predict events with 
60%-80% sensitivity and 68%-36% specificity (Shah et al., 2017). The potential of remote 
monitoring depends on the detection of validated measurements that can be predictive and 
informative of future events. As technology advances, more forms of remote monitoring will 
emerge that can be greatly expanded beyond cardiovascular disease. Challenges with remote 
monitoring center around interoperability and the need to integrate remote monitoring data with 
the patient’s electronic health record (EHR) (Yamada et al., 2020). Furthermore, while patient 
burden is lessened by minimizing travel to the site, there is greater responsibility placed on 
investigators to parse through the data. Depending on complexity of the remote monitoring 
system, clinician or statistician workload could substantially increase depending on amount of 
data that needs to be processed.   
Short Message Service (SMS) 
Prior to the development of smartphones, short message service (SMS) or texting was a popular 
digital health tool to deliver helpful information of patients in self-managing their disease. 
Texting is a low-cost digital health tool because it only requires a mobile device, not a 
smartphone. As a result, many studies using texting are localized in developing countries where 
mobile phone use is more common or for older populations who may struggle to use 
smartphones. The LEAN program utilized texting and lay health supporters to improve 
schizophrenia care in rural China and demonstrated improvements in medication adherence, 
improving symptoms, and reducing rehospitalizations (Cai et al., 2020). Even for younger 
populations, texting is still a popular form of digital health even among those with smartphones 
and mobile apps because of its ease of use and low burden on the user. Guy2Guy, an HIV 
prevention program for minority youths, specifically utilized texting because of the prevalence of 
cell phones even in underserved and low-income populations (Ybarra et al., 2018). Furthermore, 
texting-based interventions are very cost-effective compared to in-person and web-based 
interventions. In Guy2Guy, sending and receiving text messages cost less than 2 cents per 
message (Ybarra et al., 2018). While pre-exposure prophylaxis (PrEP), medication that prevents 
HIV infection, has been proven to be highly effective, reducing the risk of HIV infection by 
99%, its prohibitive cost at $2,000 a month is a major barrier for the populations at risk for HIV 
(Grant et al., 2010). Digital health interventions such as texting can be a suitable alternative. 
Similarly, many low-income families may not have computers but most have a cell phone with 
texting capabilities and thus interventions with texting may be an effective path to targeting a 
specific demographic.  
Telehealth 
Telehealth is the delivery of healthcare from one site to another between the patient and provider 
using electronic communication methods such as video conferencing or telephone calls (Centers 
for Medicare & Medicaid, 2020). Video visits have been viewed as a low cost and convenient 
method to deliver care to patients, especially those in rural areas where transportation is a major 
barrier to accessing care. Similarly, telephone calls are potentially more convenient to patients 
who have difficulties accessing the internet or using a computer. The capability to provide 
synchronous or asynchronous care without regard to distance, while still conforming to 
regulatory policies, has been seriously studied to some success. The telehealth intervention in the 
Healthline services was found to be associated with only minor clinical benefits for most 
individuals and no overall improvement in risk (Salisbury et al., 2016). Another trial from the 
Minneapolis Veterans Affairs Health Care System did not find any statistically significant 
difference between the standard of care and telehealth (Ishani et al., 2016). The use of telehealth 
in clinical trials appears to be limited but there is significant interest in validating the use of 
telehealth across a number of therapeutic areas.  
Wearables 
Wearables are small electronic devices worn on the body as accessories that contain one more 
sensor. Common devices include watches, belts, glasses, or adhesive patches. The sensors in 
wearables can track a number of different measurements from movement and position, 
electrophysiological or chemo-physiological function, or other physiological properties. 
Wearables in the form of watches, or smartwatches, have recently become exceedingly popular 
with users as they are able to track their health data in real-time. Features that attract patients 
include the ECG on the Apple Watch that was approved by the FDA to detect atrial fibrillation 
(Wetsman, 2020). Although studies only show moderate diagnostic accuracy, this technological 
advancement is a shift towards increase patient self-management of their health via personalized 
devices (Rajakariar et al., 2020). 
Connected Devices 
There are a number of additional digital health tools that are beginning to see usage. Smart scales 
are electronic weight scales that have a mobile app companion that allows users to track their 
weight and may be particularly useful for those with diabetes. Artificial pancreas for type 1 
diabetes are sophisticated systems that combine an insulin pump and continuous glucose monitor 
and use an automatic algorithm to administer real-time basal insulin delivery to patients 
(Forlenza et al., 2019). Such systems have been proven to significantly improve glycemic control 
and represent a perfect unity of digital health technologies to improve health outcomes. An 
ingestible smart pill has also been explored to track adherence but it has struggled to gain 
traction due to a number of core issues (Chai et al., 2017). Proteus Digital Health originally 
tested their smart pill in type 2 diabetes, finding that the pill and associated digital health 
offerings could assist in lowering blood pressure, blood sugar levels, and other associated 
outcomes but they track adherence levels (Frias et al., 2017). However, Proteus decided to target 
neurological disorders using the generic schizophrenia and bipolar disorder drug, Abilify. The 
cost of the generic drug, at $500-$800, combined with the device resulted in a drug-combination 
device of more than $1,600 (Landi, 2020b). This prohibitive cost in a small, disease-specific 
population combined with mixed results of the technology resulted in Proteus filing for 
bankruptcy (Landi, 2020a). Other drug-device combinations have shown some clinical efficacy 
such as the BETACONNECT system which combines an autoinjector that tracks medication 
adherence with additional digital health tools to address the needs of patients with multiple 
sclerosis but overall adoption is still limited (Limmroth et al., 2018). A successful drug-device 
product is Propeller Health’s connected asthma inhalers. In multiple studies, Propeller has 
demonstrated improved adherence, fewer symptoms, and less asthma-related emergency room 
visits (Merchant et al., 2016). Furthermore, this clinical efficacy has translated into commercial 
success in 2019 when Propeller was acquired for $225 million (Licholai, 2019). Additionally, 
Propeller revenue model is based on partnerships with pharmaceutical companies and health 
systems with no cost to the patient. (Moukheiber, 2018). 
Other 
Although most digital health tools have patient-centric designs, focused on patient satisfaction 
and needs, not all tools are made for patients. A number of digital platforms and clinical decision 
support services were designed specifically for physicians and nurses to use. These digital tools 
aid healthcare providers by streamlining the care process.  
These digital health technologies should not be viewed as separate entities where patients are 
only using one device or tool. Skill to Enhance Positivity (STEP), combined weekly phone calls 
with daily text messages and was found to reduce suicide events in adolescents over a 6-month 
period (Yen et al., 2020). In many cases, mobile apps were paired with a wearable where data 
from the wearable could be directly viewed by the user through the mobile app. STEP UP 
combined a gamification app and wearable device to encourage participants to improve their 
physical activity (Patel et al., 2019). By tracking their daily steps through the wearable and 
participating in the game through their app, participants had significantly increased physical 
activity compared with the control group (Patel et al., 2019). 
Prominent Therapeutic Areas with Digital Health   
Digital health tools are used across a variety of therapeutic areas from oral health and HIV to 
maternal health and cardiovascular disease. Given the flexibility of digital devices, it appears that 
any disease or therapeutic can utilize these devices to improve health outcomes. However, there 
are certain therapeutic areas that dominate because of the high prevalence and incidence of the 
disease. Specifically, diabetes, cardiovascular disease, and mental health appear to be 
particularly attractive targets for digital health.  
Diabetes and Wellness 
Diabetes and general health wellness through dieting and exercise is a major target for many 
digital health devices or interventions. Diabetes is a complex disease with many stages that 
require different methods of treatment. Earlier stages of diabetes focus on addressing lifestyle 
changes and better health education to improve outcomes. Diabetes self-management education 
has been shown to improve glycemic control and is a considerably easy method to address 
diabetes. With current technological advancements, delivery of training tools to individuals to 
assist them in self-managing their disease is an effective way to address diabetes. Unregulated 
digital tools are abundant from untested or validated mobile health apps that claim to improve 
diet and exercise. Furthermore, existing studies on health apps show limited improvements 
across a number of outcomes including glycemic control, weight loss, or medication adherence 
(Shah, Garg, 2015). However, there is evidence that the use of mobile apps in a weight loss 
program results in greater weight loss compared to a program without using an app (Turner-
McGrievy et al., 2013). Approved digital tools such as insulin pumps, artificial pancreases, and 
continuous glucose monitors have demonstrated substantial evidence in improving health 
outcomes. These devices have undergone numerous cycles of development. In addressing the 
lack of improvements from using mobile health apps, some developers are investigating 
gamification to improve physical activity and diet (Boulos et al., 2015).  
Cardiovascular 
Cardiovascular disease and other related health issues such as heart failure have become a 
serious issue in older adults who are at particularly high risk. These individuals may have 
multiple comorbidities and infirmities that limit their ability to maintain their health and have 
difficulties seeking healthcare. Digital health is seen as an opportunity to address gaps in care. 
Besides the common benefits of digital health across any therapeutic area, patients with 
cardiovascular disease may benefit from telemedicine and remote patient monitoring. 
Telemedicine can eliminate barriers of transportation which are particularly troublesome for 
older adults. Furthermore, remote patient monitoring can capture and monitor vital signs and 
biometrics (Krishnaswami et al., 2020). Although previous studies have shown older adults 
underutilize digital health technologies, this is rapidly changing with the COVID-19 pandemic. 
Given the high prevalence of cardiovascular disease in older patients, digital health could 
provide better real-time data for healthcare providers and result in quicker decision making and 
detection of adverse events.  
Furthermore, with the popularization of commercial ECGs via the Apple Watch, preventative 
care is also possible. Although most digital health has centered around remote monitoring 
through CIEDs, there is a shift towards using these devices to detect irregularities in an 
individual’s health.  
Mental Health Disorders 
Mental health disorders is a unique category that has been receptive to digital health 
interventions. The prevalence and incidence of mental health problems in children and young 
adults has been significantly increasing (Collishaw, 2015). This has been followed with an 
increased demand for mental health services on an already stressed healthcare system. Digital 
health devices and interventions are seen as scalable tools that improve access and meet needs 
(Hollis et al., 2017). Internet-delivered CBT is a popular intervention for mental health disorder 
but there is an increasing interest in adapting mobile health apps that focus on wellness.   
Discussion 
The Increasing Presence of Digital Health 
Digital health is undoubtedly of great interest to all stakeholders in healthcare from patients, 
physicians, healthcare organizations, to pharmaceutical companies. This interest is reflected in 
the large number of peer reviewed articles published in PubMed. Figure 3a shows the number of 
digital health studies published each year from 2005 to 2020 and the main digital health 
technology in the article. There has been exponential growth in the number of published digital 
health articles in the last few years. Although there has been consistent interest in digital health 
technologies, this interest began picking up in 2010 due to a variety of factors that created 
opportunities for exploration in digital health. The Obama administration wanted to revolutionize 
healthcare and pushed the adoption of electronic health records to improve the quality of care. 
Furthermore, cell phones had become increasingly common place and advanced, with 
smartphones emerging onto the market. This paradigm shift in the US from paper to electronic 
methods created a prime environment to combine health and technology. The ubiquity of 
smartphones and ease in creating mobile applications is reflected in the Mobile app category 
having the highest number of articles. All other categories fall short in matching the apparent 
interest stakeholders have in creating healthcare solutions through mobile apps. However, there 
are a number of notable categories that demonstrate shifting interests. Remote monitoring has 
shown a consistent presence due to the use of CIEDs, which inherently have an automatic 
monitoring component, but there has been new interest in remote monitoring beyond monitoring 
for heart failure alone.  
Figure 3. Number of Studies by Digital Health Device 
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The sharp decrease in total number of articles published in 2020 can be attributed to the COVID-
19 pandemic. Future and current clinical trials were impacted and in some cases were placed on 
hold. These delays in research impacted the ability of investigators to conduct their studies and 
subsequently publish their data. Furthermore, some investigators who already completed their 
trials and were pursing publication may have experienced delays in the review process. 
Similarly, journal editors may have struggled to review submissions in a timely matter and find 
appropriate individuals to peer review incoming articles. As a whole, the entire process from 
collecting data to publishing an article was impacted by COVID and is clearly reflected in the 
20.72% drop in articles in 2020. Figure 3b gives an in-depth view of trends from 2015-2020. 
Besides mobile apps, the number of articles on web-based solutions and texting increased. 
Increased interested and demonstrated effectiveness of CBT could be attributed to the growth in 
the web-based category since many of those interventions are delivered via the web. Similarly, 
the increasing prevalence of mobile phones combined with the low cost associated with texting 
interventions likely fueled interest in texting. In contrast, smartphones may have a more 
prohibitive cost making it less attractive digital health intervention.  
The use of the term ‘digital health’ has not been ubiquitous in addressing the use of technology 
in healthcare. While ‘digital health’ is now used as the overarching term many sub-terms are 
often used more commonly in the literature. Figure 4 lists the top terms used in the abstracts of 
articles in the literature review to refer to the use of technology in the clinical study. ‘mhealth’ is 
the most commonly used term by far, demonstrating the popularity of mobile technology in 
healthcare. While ‘ehealth’ is used as a broad term to encompass the use of electronic means in 
the delivery of healthcare. These two terms represent the vast majority of digital health clinical 
trials, using mobile devices or electronic devices. Telemedicine and telehealth are another aspect 
of digital health that often is ignored when considering digital health as a whole. Other variations 
appear in the literature but representative a small proportion. 
Table 2. Top Terms Associated with Digital Health  
 
The usage of these terms has varied across the last few years but the dominance of ‘mhealth’ or 
mobile health technologies had remained consistent as seen in Figure 5. The number of studies 
featuring ‘mhealth’ doubled from 2016 to 2018 as interest in digital health grew. Furthermore, in 
2017, the FDA finally addressed digital health in a major move by creating a Digital Health 
Action Plan. This signal by the FDA welcoming innovation in healthcare likely encouraged 
growth in an emerging field. Critically the change in top keywords demonstrate the developing 
interest in digital health as new technological advances enter the consumer market and there is a 
drive to validate these technologies. The prevalence of ‘randomized controlled trial’ in abstract is 
almost quadrupled in 2020 compared to 2017. Although many studies were protocols or pilots 
for future full length clinical trials, there clearly is greater interest in exploring digital health 
through rigorous, randomized controlled trials.  
Figure 4. Top Keywords from Digital Health Studies from 2016-2020  
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The implementation of digital health across therapeutic areas is inconsistent as seen in Figure 6. 
The most popular category, Cardiovascular, is an expansive category that includes 
cardiometabolic interventions hypertension to remote monitoring through CIEDs and wearables. 
The second and third largest categories, Diabetes and Health and Wellness, respectively, are also 
often associated with cardiovascular health. The focus of digital health in these categories is 
unsurprising given the high prevalence of cardiovascular disease and obesity in the United 
States. Digital health is being seen as a solution by many stakeholders to educate and address 
lifestyle changes for patients as preventive care solutions for diabetes and cardiovascular disease. 
Other notable therapeutic areas include mental health and cancer.  Digital health technologies for 
mental health in particular have jumped in popularity due to an improved awareness of mental 
health issues in the United States. With the COVID-19 pandemic, mental health has become 
even more prominent. One popular mindfulness app Calm, added 10 million new users and 
secured an additional $75 million investment (Wortham, 2021).   
Figure 5. Number of Studies by Therapeutic Area of Focus from 2006-2020  
  
The Potential Future of Digital Health in Clinical Trials  
There is numerous ways digital health can be implemented into the current clinical trial process 
that will not only improve current methods but also create new models for future trials (Figure 
6). From the initial protocol development, digital heath can play a critical role before patients are 
even selected.  
Figure 6. Digital Health Applications in Clinical Trials 
 
Recruitment of patients through social media or health related forums provides access to a larger 
study population and my provide access to a younger target population that would have 
otherwise been difficult to contact and recruit into a medical study. Many clinical trials lack 
generalizability because of a failure to recruit diverse patient samples during the clinical trial and 
many trials do not even report race or ethnic data (Geller et al., 2018). As a result, data for 
underrepresented racial and minority populations often comes from post-market studies after 
regulatory approval. Recruitment through social media can address issues of diversity by 
appealing to a larger population. Furthermore, retention in digital clinical trials has the potential 
to be much higher with the use of digital technology. The aforementioned minority populations 
may be hesitant to participate in clinical trials because of barriers from transportation and lost 
wage from missing work. A digital trial would cater to their schedule and allow the patient to 
participate and engage on their own time. This would improve the diversity of patients included 
in clinical research.  
Clinical trial language is often confusing to participants who may not fully understand the 
requirements before they decide to participate. This lack of understanding can result in a failure 
to follow the protocol or drop-out, both of which can negatively impact the success of a trial, 
regardless of the effectiveness of the treatment. Digital technologies can assist in addressing 
these issues by providing better communication and easing the barriers to participate in a clinical 
trial. Patients could electronically provide consent and watch pre-recorded videos that clearly 
state the requirements of the clinical trial. From the investigator or sponsor perspective, a digital 
clinical trial may be easier to manage. Previously, an investigator would be tied to the specific 
clinic or site to conduct the clinical trial but through digital technologies, investigators could be 
monitoring patients from any location. No longer restricted geographically, investigators could 
manage more patients and spend more time on decision making for treatment than logistical 
considerations. However, as clinical trials move to become more digital, the digital divide 
between those who have access to WIFI and those who do not, grows. This division exists for 
those who do not have a mobile phone, smartphone, computer, etc. and can continue to the point 
that lacking such devices can greatly impact an individual’s health outcomes.   
Digital endpoints, data generated from digital devices such as smartphones or wearables, are 
poised to radically change the way treatment can be delivered and personalized for each patient. 
By collecting data form an individual’s everyday life, investigators can have an in-depth 
understanding of the individual’s behavior and how their disease affects them. Critically, digital 
endpoints may provide sensitive measures of change in a patient’s health that previous measures 
could not capture. Although patient-reported outcomes are essential to many trials, digital 
devices can capture objective data minimizing possible recollection bias from patients. As these 
technologies mature, the flow of a patients’ data to the investigator could become a dynamic 
process. Adverse events are of great concern to investigators during a clinical trial because they 
could signal serious issues with the treatment of interest. With real-time data from patients, 
investigators could almost instantaneously respond to adverse events or possibly predict future 
events based on the data. This is greatest potential of digital health that is yet to be explored 
where real-world data is analyzed in real-time with machine learning or complex algorithms to 
make critical decision around treatment as more data is received. The clinical trial evolves 
beyond testing a treatment in a patient but becomes an interactive and dynamic process where 
decisions are made in real-time to thoroughly explore the effects of a treatment in a patient.  
Digital health may also increase the ability to perform Bayesian clinical trials that rely on 
continual updating of observed data to make decisions. Real-time data collection enables the 
Bayesian posterior distribution to reflect the most current belief about the treatment effect and 
enables decisions regarding study termination for efficacy or futility to be made sooner, 
potentially reducing the number of patients required and the overall cost of the study. While 
moving towards digital health technologies can increase the size of trial populations, reduce the 
burden of running a single trial on investigators, and provide novel measurements, there is a 
significant shift of responsibility towards the later stages of a clinical trial. Data cleaning, 
processing, and analysis will become exponentially more complex as a single patient could have 
hundreds of thousands of data points, most of which are accurate and relevant. The burden to 
analyze these data points into meaningful conclusions will fall on biostatisticians and the new 
emerging class of analysts, data scientists.   
Digital health is always evolving and could also play a role in platform trials, a new form of 
clinical trials. Platform trials have a flexible design that allows investigators to run multiple 
interventions and add or drop different arms as the trial proceeds based on data from interim 
analyses. The platform trial is not only an effective trial design when multiple therapies exist but 
also provides an ethical solution. During the Ebola crisis, a platform trial designed was deployed 
to evaluate multiple treatments and ineffective treatment arms were quickly removed without 
needing to stop the entire trial or waiting for pre-specified outcome measures (Thielman et al., 
2016). Digital health has much to offer to platform trials by providing real-time data that could 
better inform decisions to drop or add treatment arms. Interim analyses could be performed at 
more regular intervals and the ease the process of onboarding of patients to a new treatment arm. 
With the COVID-19 pandemic, it quickly became clear that digital devices could be used to 
supplement or replace critical infrastructure, such as hospitalization or clinic visits.  
A major touted benefit of digital health is the large amount of more accurate and useful data that 
can be collected to make informed decisions about an individual’s health. These assumptions 
raise critical issues around the reliability of digital health devices and what is useful data. 
Collected data may not be always be accurate and could pose serious health risks should 
treatment decision be made on inconclusive data. Furthermore, digital health may only 
exacerbate existing issues with data dredging. In recent years, the scientific community has been 
under increasing scrutiny for fabricating, exaggerating, and selectively omitting data resulting in 
the current replication crisis that many scientific studies are impossible to reproduce or replicate 
(Ioannidis, 2005). Data from digital health devices may overwhelm investigators and tacticians 
with meaningless data and result in attempts to find meaningful trends or patterns that may not 
exist. Clinical trials are extraordinarily costly and the pressure to find statistically significant 
results could increase p-hacking or other data manipulation techniques (Adda et al., 2020). 
Digital health also cannot address fundamental issues that arise from data collection such as 
sparse data bias (Greenland et al., 2016). Regardless of the total sample size, combinations of 
certain observations and risk factors can result in insufficient data that does not support estimates 
which results in this bias. Digital health may only increase the total data but cannot supplement 
data that does not exist because of lack of diversity in a study population. This enormous amount 
of data can also become a major burden the patient and clinician.  
The Evolving Regulations Around Digital Health  
With technological advancements and increasing accessibility of digital devices and tools, the 
need for regulatory oversight to ensure highly quality healthcare is critical. Although the 
healthcare industry has been notoriously slow at adopting new technologies, the prevalence of 
mobile devices and low barriers to developing mobile applications or software has caused the 
health technology sector to set record funding numbers in the last few years (Safi et al., 2018; 
Chiu et al., 2020). Organizations or individuals with no health-related background but have 
strong computer science abilities, are entering into a market that is predicted to be worth $639.4 
Bn by 2026 (PR Newswire, 2020). However, there are serious concerns about the risks 
associated with unchecked digital tools that at best provide no benefits and at worst cause undue 
harm to users. Furthermore, digital devices could result in overutilization of healthcare resources 
when patients who do not need assistance seek medical care because they are acting on 
erroneous data from their device (Wyatt et al., 2020).  Regulatory oversight is needed to ensure 
data quality, validation of devices, interoperability, data privacy, and evaluating effectiveness of 
devices on tangible health outcomes. Moreover, as we enter into an era of big data, the health 
informatics problem of what to do with an overwhelming amount of relevant or irrelevant data 
must be addressed. The U.S. Food and Drug Administration (FDA) has regulatory overview of 
digital health because of their consideration as medical devices to some extent through the 
Center of Devices and Radiological Health (CDRH). However, as digital health is applied to 
aspects of health and science in innovative methods, regulation of these technologies becomes 
unclear. To this point, stakeholders have continuously criticized the FDA for its slow regulatory 
process which they claim hinders innovation, especially for smaller companies and the FDA’s 
traditional approach to medical devices and technology is inadequate.  
In late September 2020, the CDRH launched the Digital Health Center of Excellence (DHCoE) 
to “align and coordinate digital health work across the FDA” (FDA, 2020b). The DHCoE is a 
major development from the FDA to address the growing digital health sector. It is the beginning 
of the FDA’s attempt to comprehensively address digital health with a focus on allowing 
innovation and advancement by working with selected partners. The DHCoE will cover mobile 
medical devices, artificial intelligence and machine learning (AI/ML), software as a medical 
device (SaMD), and wearables (FDA, 2020d). Rather than acting as an authoritative body, the 
DHCoE will instead function to provide regulatory advice and support to the FDA’s regulatory 
review and assist in setting research priorities for the CDRH (FDA, 2020b). Critically, the 
DHCoE will not be responsible for making marketing authorization decision (FDA, 2020b). This 
advisory role of the DHCoE is clearly demonstrated though its stated goals to “empower digital 
health stakeholders to advance healthcare by fostering responsible and high-quality digital health 
innovation” across nine functional areas (FDA, 2020b).  
Data security and privacy issues are one the greatest challenges to digital health adoption. In the 
US, HIPAA, the Health Insurance Portability and Accountability Act and later 2009 amendment, 
set the standards for health privacy. HIPAA has fallen under increasing criticism for its entity-
based privacy protections that only applies to covered entities, health plans and healthcare 
providers, and business associates, those performing services for covered entities. This narrow 
scope fails to include developers of digital health devices such as mobile apps that collects 
sensitive personal health data. The range of apps that collect health data not protected under 
HIPAA range from general wellness apps to mental health or fertility tracking apps, all of which 
include extremely sensitive data. Often times, the apps themselves offer little information about 
their privacy policies or data security (O’Loughlin et al., 2019). In contrast to HIPAA, the 
European General Data Protection Regulation (GDPR) and California Consumer Privacy Act 
focus on centering protection arounds the data itself rather than entities who use it (Bari, O’Neill, 
2019).  
A critical and still developing aspect of digital health is artificial intelligence or machine learning 
(AI/ML). The potential of AI/ML to generate new insights into diseases based on real-world data 
and offer novel solutions that could be personalized, is unmeasurable. These technologies are 
able to monitor real-time performance and continuously analyze data for ways to improve health 
care for patients (FDA, 2021). This type of digital health is yet to be thoroughly explored in 
clinical trials but the potential in AI/ML is limitless. However, AI/ML faces unique regulatory 
barriers as numerous questions around data privacy, potential for harm, and data validation exist.  
SaMD exemplifies the complexities of regulating digital health because of its broad range, 
iterative, and innovative nature. SaMD can take the form of software that determines the proper 
drug dosage for patients or software that detect and diagnoses diseases. It is a dynamic device 
whose risk can vary widely. Digital therapeutics (DTx) is one prominent category of devices that 
fulfill the definition of SaMD (Digital Therapeutics Alliance, n.d.). This software can deliver 
evidence-based therapeutic interventions that assist patients in the prevention, management, and 
treatment of numerous diseases. Digital therapeutics can increase patient access to novel 
treatments that traditional therapies were unable to address. The varied forms that SaMD can 
take presents a unique challenge. The FDA recently approved the first game-based digital 
therapeutic, EndeavorRx, through the de novo pathway, a regulatory process for novel medical 
devices, based on data from five clinical studies (Akili Interactive, 2020a). In the prospective 
randomized controlled study, EndeavorRx demonstrated improved objectively measured 
inattention in attention-deficit/hyperactivity disorder (ADHD) pediatric patients with minimal 
adverse events (Kollins et al., 2020). Since its approval, data from its multi-site open-label study 
investigating the impact of the intervention on the daily life, has found early exploratory 
evidence that following treatment, children had improved math and reading skills (Akili 
Interactive, 2020b).  
Another illustration of SaMD can be found in artificial intelligence and machine learning 
(AI/ML). The potential of AI/ML to generate new insights into diseases based on real-world data 
and offer novel solutions that could be personalized, is unmeasurable. These technologies are 
able to monitor real-time performance and continuously analyze data for ways to improve health 
care for patients (FDA, 2021). 
Digital Health Software Precertification Program (Pre-Cert) that was launched as a part of the 
Digital Health Innovation Action Plan from the CDHR in 2017 (FDA, n.d. innovation action 
plan). Reimaging digital heath product oversight materialized in the formation of Pre-Cert. This 
program was designed to allow for faster review of medical devices and reduce the number of 
submissions the FDA receives. These goals would be achieved by “pre-certifying” certain digital 
health developers who demonstrated “a culture of quality and organizational excellence based on 
objective criteria” (FDA, n.d.a). Those who are pre-certified could then market their low-risk 
devices without additional FDA review or could receive a streamlined review (FDA, 2020a). 
Participating developers could potentially have their real-world data be used to support the 
devices regulatory status and provide further evidence of its safety and effectiveness. Pre-Cert 
1.0 officially began in 2019 and selected nine partners: Apple, Fitbit, Johnson & Johnson, Pear 
Therapeutics, Phosphorus, Roche, Samsung, Tidepool, and Verily (Google) (FDA, n.d.d). One of 
the partners in the program, Pear Therapeutics, is a prescription digital therapeutic developer 
who has already gone through the FDA approval process for one of its digital therapeutics. 
reSET, which helps treat patients with substance use disorder, was approved in 2017 under the 
De Novo pathway after it demonstrated improved abstinence and treatment retention in clinical 
studies (Pear Therapeutics, 2017). 
However, the FDA’s traditional framework for regulation falls short for devices that constantly 
adapt and change. The FDA has approved a so-called “locked” AI/ML-based SaMD but the true 
potential of these devices lies in “learned” algorithms. Locked algorithms cannot evolve based 
on new data received and remain in a frozen but tested and verified state. However, for AI/ML-
based SaMD, continual innovation utilizing received data is core to the function of the device but 
this innovation can threaten its own regulatory approval. To address these issues, in 2019, the 
FDA proposed a regulatory framework for premarket review of AI/ML-driven software 
modifications (FDA, n.d.c). This framework, the total product lifecycle approach is based on the 
precertification program which accounts for rapid innovation and “learned” or adaptive AI/ML 
algorithms. However, the process for approval and implementation is still murky at best because 
of the complex challenges AI/ML poses to regulatory oversight. Even prior to undergoing 
regulatory approval, how does the FDA decide if an AL/ML-based SaMD produce needs 
approval? Once a device is approved, given its iterative nature, how does the FDA ensure that 
device remains safe and effective for patients over time? Will all iterations require FDA approval 
and how is the risk associated with different iterations? Clearly, these are serious concerns that 
will only continue to grow as technology advances. Some have suggested that the FDA should 
take a system approach, rather than a product approach, because AI/ML-based SaMD are highly 
dynamic and are heavily influenced by the environment and external factors (Gerke et al, 2020). 
However, a system’s approach would require the FDA to consider information outside of its 
normal purview and may go beyond its legal authority. Information on reimbursement from 
insurers, data usage, data quality, social behavioral biases, interoperability would greatly 
improve the ability for the FDA to regulate AI/ML-based SaMD but place an enormous burden 
on the FDA (Gerke et al, 2020). Recent controversy on twitter’s alleged racist AI, where the 
algorithm chooses to display light-skinned individuals in thumbnails over dark-skinned 
individuals, highlights how AI/ML could further introduce racism into healthcare. Should these 
social considerations be ignored, AI/ML-based SaMD could perpetuate and re-enforce racist 
perceptions and further health inequities in a system struggling to establish trust in minority 
communities because the underlying data which trained the algorithms is biased. 
The COVID-19 pandemic has greatly accelerated the FDA’s response to digital health use in 
clinical trials. According to Marra et al (2020), prior to the pandemic, almost 1200 clinical trials 
incorporated a digital health device and once the pandemic began to disrupt trial processes many 
investigators turned to digital health tools from remote patient monitoring to telehealth to ensure 
the trial could proceed without comprising patient safety. In response to the pandemic and to 
minimalize its disruption, the FDA issued a guidance document on how trial sponsors could 
continue their operations. This sudden shift to utilizing digital health devices for many clinical 
trials will provide much insight from investigators and study participants to the FDA on how it 
will approach future regulatory guidance.  
Conclusion 
Interest in digital health has exploded in the past few years with an exponential increase in the 
number of articles on digital health. Furthermore, this interest has expanded beyond applying 
known digital health solutions to new therapeutic areas to creating and tailoring devices 
specifically for certain diseases and indications. While certain devices, such as a mobile app, can 
have universal application and utility, truly successful digital health devices are likely to be 
specifically tailored and designed for their targeted disease.  
As digital health enters into a mature phase, current prominent therapeutic areas such as diabetes 
and cardiovascular disease will become saturated with common digital health devices. True 
digital health maturity will manifest as uniquely designed devices specific for its indication. 
However, prior to this maturation, general application of digital health devices is common 
because of their wide utility. As such, many see clinical trials to be a prime venue to utilize the 
potential benefits of digital health. Digital health can not only reduce costs and patient burden 
but also introduce novel methods of data collection and data analysis. The true value of digital 
health in clinical trials has yet to be fully explored but should not be underestimated.  
Limitations  
There were a number of limitations in this literature review. While the PubMed search was broad 
and included a number of digital health related keywords, it is likely that some digital health 
technologies or devices were not included because the language used in digital health is still 
evolving. Although PubMed is an extensive database of biomedical literature, digital health 
devices and solutions exist outside of this literature and may not be rigorously tested and 
published in journals. A number of grey literature articles were included to supplement potential 
gaps but some digital health technologies not yet published were likely not included. Many 
clinical trials do not publish their findings in peer reviewed journals and thus this analysis would 
under count the total number of digital health clinical trials. Furthermore, stakeholders may 
already be utilizing digital health technologies in their clinical trials but have not made that 
information public. An assumption was made that the number of published articles in PubMed is 
correlated with digital health interest and growth. However, a number of potential delays such as 
the article review process could have delayed publications to a later year.  
Future Directions 
This thesis broadly explored the digital health landscape including all potential devices across all 
therapeutic categories. Future research could investigate the application of a specific digital 
health device in a therapeutic area and the benefits of said device. With more and more clinical 
trials including some digital health component, there is still much to be explored about how 
digital health can assist in expanding beyond traditional clinical trials.  
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